Other: Standard treatment according to the Clinical protocols ( DrugBank: - )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 49 | 全身性エリテマトーデス | 1 |
| 51 | 全身性強皮症 | 1 |
| 235 | 副甲状腺機能低下症 | 1 |
49. 全身性エリテマトーデス
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04184258 (ClinicalTrials.gov) | July 1, 2019 | 1/12/2019 | Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells | Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Olfactory Mucosa Derived Mesenchymal Stem Cells | Systemic Lupus Erythematosus | Biological: Pooled mesenchymal stem cell;Other: Standard treatment according to the Clinical protocols | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Belarusian State Medical University | Completed | 18 Years | 75 Years | All | 7 | Phase 1/Phase 2 | Belarus |
51. 全身性強皮症
臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05214014 (ClinicalTrials.gov) | March 1, 2022 | 29/11/2021 | Treatment of Systemic Sclerosis With Autologous Regulatory ?-cells | Treatment of Patients With Systemic Sclerosis With Autologous Regulatory ?-cells | Systemic Sclerosis | Biological: Autologous Regulatory ?-cells;Other: Standard treatment according to the clinical protocols | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Belarusian State Medical University | Not yet recruiting | 18 Years | 80 Years | All | 30 | Phase 1/Phase 2 | NULL |
235. 副甲状腺機能低下症
臨床試験数 : 88 / 薬物数 : 128 - (DrugBank : 25) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05186883 (ClinicalTrials.gov) | March 1, 2022 | 1/12/2021 | Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells | Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells | Postoperative Hypoparathyroidism | Biological: Allogenic parathyroid cells;Other: Standard treatment according to the Clinical protocols | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Belarusian State Medical University | Not yet recruiting | 18 Years | 70 Years | All | 20 | Phase 1/Phase 2 | NULL |